Navigation Links
GPhA Annual Meeting Focuses on Industry Opportunities and Challenges for 2008
Date:2/12/2008

BOCA RATON, Fla., Feb. 12 /PRNewswire/ -- More than 400 generic industry leaders, financial experts and political officials gathered today for the Generic Pharmaceutical Association (GPhA) Annual Meeting to discuss the critical issues facing the generic industry in 2008. With the theme of "Generics: The Right Choice for Better Health," conference participants discussed the industry opportunities and challenges in this important legislative and election year.

"Voters are going to the polls with access to affordable health care at the top of their minds," said GPhA President Kathleen Jaeger. "Generics -- and biogenerics -- are the solution to reducing health care costs while increasing access to quality care. With generics saving consumers and the federal government billions of dollars a year, it's clear that generics are the right choice for better health."

Today 65% of all U.S. prescriptions dispensed are filled with generics, at costs of 30% to 80% less than brands. This offers substantial savings for consumers, state governments and the health care system. In fact, a 1% increase in generic use saves consumers $4 billion annually.

On Capitol Hill and in state capitals across the country, the generic industry will be working to help consumers receive greater access to affordable medicines by:

-- Encouraging passage of federal legislation to create a safe and

workable Food and Drug Administration (FDA) approval pathway that

provides timely access to biogeneric medicines. Brand

biopharmaceutical medicines can cost hundreds of thousands of dollars

per patient, per year. Safe and effective generic versions of

biopharmaceutical medicines, or biogenerics, would save consumers

billions of dollars and provide countless patients with access to

lifesaving treatments.

-- Removing longstanding barriers to consumer access to generics

including:

* Ensuring that FDA implements the citizen petition law passed by

Congress in 2007 to curb brand drug company efforts to delay generic

competition.

* Blocking the marketing of an authorized generic (the brand company's

own product repackaged and marketed either through a subsidiary or

third party) during the 180-day exclusivity period awarded to the

first generic competitor.

-- Providing sufficient supplemental Congressional funding for the FDA's

Office of Generic Drugs Increasing FDA-industry communications.

-- Addressing changes to the Medicaid pharmacy reimbursement rules to

ensure that they do not harm consumers' access to generics.

-- Approving free trade agreements, similar to the recent U.S.-Peru Free

Trade Agreement, that balance pharmaceutical innovation with access to

affordable generic medicines.

-- Enacting legislation to promote e-prescribing to increase patient

safety.

-- Stopping state "carve out" legislation that bars generic substitution

for various therapeutic classes of medicines. Carve outs cost states

millions of dollars.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 65% of the total prescriptions dispensed in the United States, but only 20.5% of all dollars spent on prescription drugs.


'/>"/>
SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
2. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
3. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
4. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
7. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
8. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):